However, PR-targeted therapies have failed to progress significantly in clinical therapy for breast cancer, due to confusion regarding the effects of progestogens, which exhibit both stimulatory and inhibitory effects on angiogenesis [9,136]. The gene discussed is PGR; the disease is breast carcinoma.